Thu, Oct 2, 2014, 6:06 AM EDT - U.S. Markets open in 3 hrs 24 mins


% | $
Quotes you view appear here for quick access.

Aegerion Pharmaceuticals, Inc. (AEGR) Message Board

  • ra9909 ra9909 Oct 18, 2012 3:27 PM Flag

    AEGR was WAY OVERBOUGHT, on the misguided assumption that ISIS would get rejected

    WRONG! Hope you were smart enough to sell before the vote, stock now pulling back a whopping $2 from the high. Genzyme says to you longs, NOT SO FAST, PEOPLE! And ISIS is a HUGELY better investment long-term, over 25 drugs in pipeline, 6 are currently in Phase 2. Lots of potential lottery tickets in there, folks!

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • I agree as a long term hold ISIS is better (I held it for two years), but AEGR is a better short term hold through FDA approval. There is still a reasonable chance ISIS will be required to provide additional cancer and liver tox data before approval by the FDA. A 9-6 vote with one panelist stating his was a "weak yes" is going to weigh heavily on the FDA, since they have Lopitimade which only had 2 dissenters. If they delay approval of Mipo there is still a viable drug with better efficacy available to this patient population. There is also the possibility that Sanofi/Genzyme or other large pharma will buy AEGR. In the meantime, for docs who have these patients, which drug is prescribed is a no-brainer.

33.56+0.18(+0.54%)Oct 1 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.